Telitacicept
drugOn this page
Summary
Telitacicept (CHEMBL5095293) is a phase-3 clinical-stage protein; indicated across 8 conditions including sjogren syndrome and iga glomerulonephritis.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Protein
- Indications: 8 conditions
- Clinical trials: 45
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL5095293 |
| Name | Telitacicept |
| Type | Protein |
| Max phase | 3 |
Also known as: Telitacicept, TELITACICEPT
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
8 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| Sjogren syndrome | 3 | MONDO:0010030 | EFO:0000699 |
| IgA glomerulonephritis | 3 | MONDO:0005342 | EFO:0004194 |
| myasthenia gravis | 3 | MONDO:0009688 | EFO:0004991 |
| systemic lupus erythematosus | 3 | MONDO:0007915 | MONDO:0007915 |
| nephrotic syndrome | 3 | MONDO:0005377 | EFO:0004255 |
| antiphospholipid syndrome | 2 | MONDO:8000010 | EFO:0002689 |
| lupus nephritis | 2 | MONDO:0005556 | EFO:0005761 |
| diffuse scleroderma | 2 | MONDO:0005019 | EFO:0000404 |
Clinical trials
Total trials: 45.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 13 |
| PHASE2 | 11 |
| PHASE4 | 8 |
| Not specified | 8 |
| PHASE2/PHASE3 | 2 |
| PHASE1 | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05962840 | PHASE4 | RECRUITING | Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM) |
| NCT05965284 | PHASE4 | RECRUITING | Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM) |
| NCT06546540 | PHASE4 | RECRUITING | The Safety and Efficacy of Telitacicept in the Treatment of Systemic Sclerosis |
| NCT06677801 | PHASE4 | ACTIVE_NOT_RECRUITING | Immune Cell Subsets in SLE Patients Treated with Telitacicept |
| NCT06723548 | PHASE4 | NOT_YET_RECRUITING | Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis |
| NCT07008196 | PHASE4 | NOT_YET_RECRUITING | Telitacicept for the Treatment of Refractory RA |
| NCT05666336 | PHASE4 | UNKNOWN | Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients |
| NCT05899907 | PHASE4 | UNKNOWN | Efficacy and Safety of Telitacicept in Early SLE |
| NCT05596708 | PHASE2/PHASE3 | NOT_YET_RECRUITING | Study of Telitacicept in Patients With Refractory IgA Nephropathy |
| NCT05799287 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study of Telitacicept for IgA Nephropathy (TELIGAN) |
| NCT06125405 | PHASE3 | RECRUITING | Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome |
| NCT06456580 | PHASE3 | RECRUITING | A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) |
| NCT07052981 | PHASE3 | NOT_YET_RECRUITING | Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis |
| NCT07098897 | PHASE3 | ACTIVE_NOT_RECRUITING | To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy |
| NCT07249632 | PHASE3 | RECRUITING | A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) |
| NCT07355257 | PHASE2/PHASE3 | NOT_YET_RECRUITING | TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM) |
| NCT07404865 | PHASE3 | RECRUITING | Phase 3 Study of Telitacicept in Active Primary Sjögren’s Disease |
| NCT07495033 | PHASE3 | NOT_YET_RECRUITING | Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease |
| NCT05306574 | PHASE3 | TERMINATED | A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1) |
| NCT05339217 | PHASE3 | UNKNOWN | Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus |
| NCT05673993 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren’s Syndrome |
| NCT05737160 | PHASE3 | COMPLETED | Study of Telitacicept in Generalized Myasthenia Gravis |
| NCT06456567 | PHASE3 | WITHDRAWN | A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2) |
| NCT05680480 | PHASE2 | RECRUITING | A Study of Telitacicept in Lupus Nephritis |
| NCT05998759 | PHASE2 | RECRUITING | Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia |
| NCT06375005 | PHASE2 | RECRUITING | Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis |
| NCT06614985 | PHASE2 | NOT_YET_RECRUITING | The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy |
| NCT06656962 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN) |
| NCT07111338 | PHASE2 | ACTIVE_NOT_RECRUITING | Telitacicept for PGNMID: A Single-Arm Study |
| NCT07340463 | PHASE2 | RECRUITING | The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment |
| NCT07522099 | PHASE2 | RECRUITING | Chinese Adults With Kidney Disease |
| NCT04905212 | PHASE2 | TERMINATED | A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy |
| NCT05078710 | PHASE2 | TERMINATED | Telitacicept in Primary APS Patients |
| NCT05929248 | PHASE2 | UNKNOWN | Exploring the Therapeutic Effect of Telitacicept on Lupus Erythematosus Complicated With Thrombocytopenia |
| NCT06315530 | PHASE2 | COMPLETED | Effect of Telitacicept on Antibody Titers in Primary APS Patients |
| NCT05247203 | PHASE1 | COMPLETED | Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus |
| NCT05687526 | PHASE1 | COMPLETED | A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus |
| NCT06394063 | Not specified | RECRUITING | Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients |
| NCT06654596 | Not specified | RECRUITING | Efficacy and Safety of Telitacicept in IgAN |
| NCT06827587 | Not specified | NOT_YET_RECRUITING | Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).